Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous fungizone®

Pharmaceutical Research

Volumn 26, Issue 6, 2009, Pages 1324-1331

  Italia, J L ^a   Yahya, M M ^b   Singh, D ^b   Ravi Kumar, M N V ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Amphotericin B; Bioavailability; Biodegradable; Nephrotoxicity; Oral delivery

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; NANOPARTICLE; POLYGLACTIN;

ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; HEMOLYSIS; LEISHMANIASIS; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SYSTEMIC MYCOSIS;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; BLOOD UREA NITROGEN; CREATINE; HEMOLYSIS; LACTIC ACID; MALE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY;

EID: 67349276996     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9841-2     Document Type: Article

References (23)

1. C. Junhass K. A. Marr 2002 Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr. Opin. Infect. Dis. 15 347 353
2. D. P. Kontoyiannis G. P. Bodey 2002 Invasive aspergillosis in 2002: an update Eur. J. Clin. Microbiol. Infect. Dis. 21 162 172 doi:10.1007/s10096-002- 0699-z (Pubitemid 34328000)
3. R. D. Meyer 1992 Current role of therapy with amphotericin B Clin. Infect. Dis. 14 S154 S160
4. C. Gates R. J. Pinney 1993 Amphotericin B and its delivery by liposomal and lipid formulations J. Clin. Pharm. Ther. 18 147 153 doi:10.1111/j.1365-2710. 1993.tb00605.x (Pubitemid 23187038)
5. C. P. Thakur A. K. Pandey G. P. Sinha S. Roy K. Behbehani P. Oilliaro 1996 Comparison of three treatment regimens with liposomal amphotericin B (Ambisome) for visceral leishmaniasis in India: a randomized dose finding study Trans. R. Soc. Trop. Med. Hyg. 90 319 322 doi:10.1016/S0035-9203(96)90271-0 (Pubitemid 26188890)
6. S. Sundar M. Rai 2002 Advances in the treatment of leishmaniasis Curr. Opin. Infect. Dis. 15 593 598 (Pubitemid 36026972)
7. S. Arikan J. H. Rex 2001 Lipid-based antifungal agents: current status Curr. Pharm. Des. 5 93 415 (Pubitemid 32409727)
8. H. A. Gallis R. H. Drew W. W. Pickard 1990 Amphotericin B: 30 years of clinical experience Rev. Infect. Dis. 12 308 329 (Pubitemid 20118658)
9. R. H. Müller K. Peters 1998 Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique Int. J. Pharm. 160 229 237 doi:10.1016/S0378-5173(97)00311-6 (Pubitemid 28083096)
10. O. Kayser C. Olbrich V. Yardley A. F. Kiderlen S. L. Croft 2003 Formulation of amphotericin B as nanosuspension for oral administration Int. J. Pharm. 254 73 75 doi:10.1016/S0378-5173(02)00686-5 (Pubitemid 36259814)
11. V. Risovic M. Boyd E. Choo K. M. Wasan 2003 Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats Antimicrob. Agents Chemother. 47 3339 3342 doi:10.1128/AAC.47.10.3339-3342.2003 (Pubitemid 37229601)
12. R. Santangelo P. Paderu G. Delmas Z. W. Chen R. Mannino L. Zarif D. S. Perlin 2000 Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis Antimicrob. Agents Chemother. 44 2356 2360 doi:10.1128/AAC.44.9.2356-2360.2000 (Pubitemid 30650879)
13. A. K. Meena D. Venkat Ratnam G. Chandraiah D. D. Ankola P. Rama Rao M. N. V. Ravi Kumar 2008 Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure® in treating hyperlipidemia Lipids 43 231 241 doi:10.1007/s11745-007-3142-5
14. S. McClean E. Prosser E. Meehan D. O'Malley N. Clarke Z. Ramtoola D. Brayden 1998 Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia Eur. J. Pharm. Sci. 6 153 163 doi:10.1016/S0928-0987(97)10007-0 (Pubitemid 28164286)
15. G. Mittal D. K. Sahana V. Bhardawaj M. N. V. R. Kumar 2007 Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo J. Control Release 119 77 83 doi:10.1016/j.jconrel.2007.01.016 (Pubitemid 46561546)
16. U. Bilati E. Allemann E. Doelker 2005 Development of a nonoprecipitation method intended for entrapment of hydrophilic drugs into nanoparticles Eur. J. Pharm. Sci. 24 68 69 doi:10.1016/j.ejps.2004.09.011 (Pubitemid 40051288)
17. K. Dillen J. Vanderwoot G. V. D. Mooter A. Ludwig 2006 Evaluation of ciprofloxacin loaded Eudragit® RS100 or RL100/PLGA nanoparticles Int. J. Pharm. 314 72 82 doi:10.1016/j.ijpharm.2006.01.041
18. D. K. Sahana G. Mittal V. Bhardwaj M. N. V. Ravi Kumar 2008 PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug J. Pharm. Sci. 97 1530 1542 doi:10.1002/jps. 21158
19. S. R. Jameela N. Suma A. Jayakrishna 1997 Protein release from poly (ε-caprolactone) microspheres prepared by melt encapsulation and solvent evaporation techniques: a comparative study J. Biomater. Sci. Polym. Ed. 8 457 466 doi:10.1163/156856297X00380 (Pubitemid 27196922)
20. C. Paulo M. S. L. Jose 2000 Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 125 (Pubitemid 32288781)
21. S. Hariharan V. Bhardwaj I. Bala J. Sitterberg U. Bakowsky M. N. V. Ravi Kumar 2006 Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy Pharm. Res. 23 184 195 doi:10.1007/s11095-005-8418-y (Pubitemid 43214675)
22. J. L. Italia D. K. Bhatt V. Bhardwaj K. Tikoo M. N. V. Ravi Kumar 2007 PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral J. Control Release 119 197 206 doi:10.1016/j.jconrel.2007.02.004 (Pubitemid 46778760)
23. A. W. Ritschel, and G. L. Kearns, Pharmacokinetic parameters of important drugs. Handbook of Basic Pharmacokinetic. American Pharmaceutical Association, Washington, p 484 (1998)